Please login to the form below

Not currently logged in
Email:
Password:

Dr Edward Browne joins Sygnature Discovery

He becomes associate director of drug metabolism and pharmacokinetics

Sygnature Discovery Dr Edward BrowneNottingham, UK-based Sygnature Discovery has expanded its drug metabolism and pharmacokinetics (DMPK) team with the appointment of Dr Edward Browne as associate director.

Dr Browne (pictured right) moves to the drug discovery service provider from GlaxoSmithKline, where he most recently served as head of DMPK for its Singapore operations.

He first joined GSK as a bioanalytical scientist in 2000, before working at Simbec Research in a similar post.

In 2005, Dr Browne re-joined GSK, becoming a team leader in its neural pathways discovery performance unit in Singapore before taking on increasingly senior roles.

Dr Timothy Schulz-Utermoehl, director of DMPK at Sygnature Discovery, said: “I am delighted to welcome Ed to the team here at Sygnature.

“Ed brings significant DMPK and drug discovery experience to our rapidly expanding department as we continue to build our CNS expertise and large molecule bio analysis.”

24th October 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics